Marksans Pharma Ltd
NSE:MARKSANS

Watchlist Manager
Marksans Pharma Ltd Logo
Marksans Pharma Ltd
NSE:MARKSANS
Watchlist
Price: 181.61 INR -0.32%
Market Cap: 82.3B INR

Marksans Pharma Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Marksans Pharma Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Marksans Pharma Ltd
NSE:MARKSANS
Cash from Operating Activities
₹2B
CAGR 3-Years
17%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash from Operating Activities
₹58.8B
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash from Operating Activities
₹42.9B
CAGR 3-Years
14%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash from Operating Activities
₹127.2B
CAGR 3-Years
46%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Lupin Ltd
NSE:LUPIN
Cash from Operating Activities
₹47.3B
CAGR 3-Years
N/A
CAGR 5-Years
146%
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash from Operating Activities
₹19.4B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

Marksans Pharma Ltd
Glance View

Marksans Pharma Ltd. is a prominent player in the global pharmaceutical landscape, with its roots deeply embedded in the meticulous world of drug formulation and manufacturing. The company weaves its narrative through a robust portfolio that spans various therapeutic segments, including pain management, oncology, cardiovascular health, and anti-diabetic medications. By navigating the complexities of regulated markets such as the United States, the United Kingdom, and Australia, Marksans has engineered a business model that emphasizes quality, compliance, and innovation. This framework allows the company not only to design and develop a diverse array of generic pharmaceutical products but also to efficiently cater to a global clientele through its cost-effective yet high-quality manufacturing processes. Central to Marksans' success is its strategic integration of research and development with flexible manufacturing capabilities, housed in state-of-the-art facilities across Goa and India. These facilities, certified by leading international regulatory bodies, enable Marksans to maintain a competitive edge in both product delivery and diversification. By leveraging strategic partnerships and continuously expanding its product portfolio, it thrives in the dynamic pharmaceutical market. Revenue generation flows seamlessly through its vertically integrated operations, which streamline the journey from drug conception to distribution. Through these concerted efforts, Marksans not only bolsters its financial standing but also contributes significantly to the broader field of global healthcare, aligning economic performance with a commitment to health and well-being.

MARKSANS Intrinsic Value
185.26 INR
Undervaluation 2%
Intrinsic Value
Price

See Also

What is Marksans Pharma Ltd's Cash from Operating Activities?
Cash from Operating Activities
2B INR

Based on the financial report for Sep 30, 2025, Marksans Pharma Ltd's Cash from Operating Activities amounts to 2B INR.

What is Marksans Pharma Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-4%

Over the last year, the Cash from Operating Activities growth was -6%. The average annual Cash from Operating Activities growth rates for Marksans Pharma Ltd have been 17% over the past three years , -4% over the past five years .

Back to Top